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PRESERVATION OF PULMONARY DIFFUSING CAPACITY WITH ORAL BE-
CLOMETHASONE DIPROPIONATE: RESULTS FROM TWO RANDOMIZED,
PLACEBO-CONTROLLED TRIALS IN ALLOGENEIC GRAFT RECIPIENTS
Chien, J.W., Gooley, T., Sakai, M., Schoch, H.G., McDonald, G.B. Fred
Hutchinson Cancer Research Center, Seattle, WA.
Randomized trials show that oral BDP allows rapid tapering of
prednisone while controlling gastrointestinal GVHD following al-
logeneic hematopoietic cell transplant and results in better out-
comes (Blood 2007;109:4557–63). In reviewing adverse event
data, we noted fewer pulmonary infiltrates in the BDP arm, perhaps
because oral BDP is metabolized in the gut to the potent immuno-
suppressive metabolite 17-beclomethasone monopropionate (17-
BMP), some of which is transported via the portal circulation and
pulmonary artery directly to the lung. To test the hypothesis that
17-BMP preserved lung function after HCT, we reviewed prospec-
tive pulmonary function tests in 120 randomized patients who had
been randomized at FHCRC.
Methods:Two studies had randomized patients with GI GVHD
to a 10-day induction course of prednisone 1 mg/kg/d for 10 days
plus either oral BDP 8 mg/d or placebo. Patients whose symptoms
were under control at study day 10 had prednisone tapered rapidly
but study drug was continued for 30–50 days. GVHD treatment
failures were treated with prednisone 1–2 mg/kg/d. Change in
lung function was assessed by comparing pulmonary function tests
(PFTs: FEV1, FVC, TLC, DLCO) performed prior to start of con-
ditioning to those obtained post-transplant at day 80, blinded to
randomization assignment. Results: Sixty patients had been ran-
domized to oral BDP and the same number to placebo. Serial
PFTs at day 80 were available from 44 and 50 patients on placebo
and BDP, respectively. Significantly fewer patients randomized to
BDP (55%) had deterioration of diffusing capacity by transplant
day 80, compared to placebo (79%), p 5 0.02. No such differences
were noted in other PFT parameters. Conclusions: These data
suggest that oral BDP may have a protective effect on early decline
in pulmonary diffusing capacity, which commonly occurs by day 80
after transplant because of interstitial lung injury. We hypothesize
that preservation of diffusing capacity was due to delivery of the po-
tent immunosuppressive metabolite 17-BMP to the lungs via GI
mucosa, portal vein, and pulmonary artery.
Proportion of patients whose PFTs decreased from pre-HCT baseline to
transplant day 80 and magnitude of changes, by randomization
assignment (chi square test)
Baseline toHCT day 80
(# decreased/total #)Magnitude of % change
(mean, range)PFT Placebo BDP P Placebo BDPDLCO 32/44 (79%) 27/49 (55%) .02 27.95 (240, 123) 10.57 (274, 1115)FVC 24/44 (55%) 25/50 (50%) .66 21.85 (220, 116) 10.34 (230, 135)TLC 25/42 (60%) 29/50 (58%) .88 21.67 (220, 123) 11.41 (225, 157)FEV1 21/44 (48%) 25/50 (50%) .83 20.55 (225, 1109) 11.61 (227, 134)8
FACTORS AFFECTING 100-DAY AND 1-YEAR MORTALITY FOLLOWING
MYELOABLATIVE SINGLE-UNIT CORD BLOOD TRANSPLANTATION IN
ADULTS AND ADOLESCENTS: A COMPREHENSIVE META-ANALYSIS OF
CIBMTR, NCBP AND EUROCORD
Cohen, Y.C.1, Scaradavou, A.2, Stevens, C.E.2, Rubinstein, P.2,
Gluckman, E.3, Pacheco, D.3, Eapen, M.4, Horowitz, M.M.4,Shpall, E.J.5, Laughlin, M.J.6, Nagler, A.7, Daniely, Y.1,
Barishev, R.8, Olmer, L.8, Freedman, L.S.8. 1Gamida Cell Ltd., Jerusa-
lem, Israel; 2New York Blood Center, NY, NY; 3Hospital Saint Louis,
Paris, France; 4Medical College ofWisconsin,Milwaukee,WI; 5MDAn-
derson Cancer Center, Houston, TX; 6Cleveland Cord Blood Center,
Cleveland, OH; 7Sheba Medical Center, Tel Hashomer, Israel; 8Gertner
Institute for Epidemiology and Health Policy Research, Tel Hashomer,
Israel.
A retrospective meta-analysis was conducted to examine factors
affecting mortality following myeloablative, single-unit cord blood
transplantation (CBT) for hematological malignancies in adoles-
cents and adults. Data was collected from three cord-blood trans-
plant registries, Center for International Blood and Marrow
Transplant Research (CIBMTR), National Cord Blood Program
(NCBP) and Eurocord, and included all records of single, unmanip-
ulated, first myeloablative allogeneic CBT conducted in North
America or Europe from 1995 to 2005, with HLA match $4/6, in
patients with acute leukemia, chronic myeloid leukemia, myelodys-
plastic syndrome or lymphoma aged 12 to 55, for which 100-day
survival data was available. Data was pooled after screening for spec-
ified eligibility criteria, creation of common classifications, check-
ing for integrity and consistency, and removal of duplicates.
Analysis involved comparison of survival outcomes according to
known and exploratory prognostic factors. These covariates were
used to build logistic regression models for 100-day and 1-year
mortality. Five hundred and fourteen of 742 potential records
were found to meet eligibility criteria and were included in the
meta-analysis. Overall 100-, 180-day and 1-year mortalities (Ka-
plan-Meier) were 44%, 56% and 68%, respectively with no signif-
icant heterogeneity across registries. Some heterogeneity was
observed in the prognostic factors. Multivariate analysis showed
cell dose\ 2.5  107/Kg (Odds Ratio 2.74, p\ 0.0001), disease
stage (p 5 0.04), positive CMV sero-status (OR 1.46 p 5 0.056),
age (p5 0.002), female gender (OR 1.45, p5 0.059) and transplant
center with less CBT experience (contribution of\10 registry re-
cords, OR 2.02, p 5 0.0007) to be associated with higher 100-day
mortality; A multivariate model predictive of 1-year mortality in-
cluded similar covariates: cell dose (OR 1.66, p 5 0.011), disease
stage (p 5 0.03), CMV (OR 2.25 p\ 0.0001), age (p 5 0.02) and
center experience (OR 2.25, p 5 0.0002). Transplant year was not
independently predictive of mortality in either of these models.
This is the first meta-analysis to pool records from three major
CBT registries in the US and Europe. Despite differences in prac-
tice patterns, survival data showed remarkable homogeneity. The
resulting models will be used in the analysis of the Pivotal Study
of StemEx; transplantation of cord blood expanded ex vivo with
a copper chelator along with the non-manipulated fraction of the
same cord blood unit.9
RISK FACTORS ASSOCIATED WITH GRAFT FAILURE AFTER UMBILICAL
CORD BLOOD TRANSPLANTATION (UCBT): A SINGLE CENTER ANALYSIS
IN 539 PATIENTS
Doshi, K., Brunstein, C.G., Cao, Q., Wagner, J.E. University of Minne-
sota, Minneapolis, MN.
UCBT has proved to be a viable alternative for pediatric and adult
patients who do not have an HLA matched related or unrelated do-
nor. However, the incidence of graft failure (GF), an often fatal
complication, has been reported to be as high as 30% in some series.
Therefore, we attempted to identify potential risk factors associated
with GF in 539 patients (adult, n 5 297; pediatric, n 5 242) trans-
planted with UCB at University of Minnesota between 1994–2006.
Patients received one (n 5 261) or two (n 5 278) UCB units after
a myeloablative (MA, n 5 338) or reduced intensity (RIC, n 5
201) conditioning regimen for malignant (n 5 418) or non-malig-
nant (n 5 121) disease. GF was defined as evidence of \5%5
